News

knee.injx_.lat_.jpg

CDC: Outbreak of Arthrocentesis Related Septic Arthritis Cases in New Jersey

Jack Cush, MD

In March 2017, an outbreak of 41 cases of septic arthritis associated with intra-articular injections administered at an single outpatient practice occurred in New Jersey. A public health investigation identified multiple breaches of recommended infection prevention practices during the preparation and administration of PBP products. The intraarticular injections were done using fluoroscopic visualization. The CDC has reported the results of its investigation.

FDA.Safety.jpg

August 2nd AAC Meeting: FDA Concerns Over Sirukumab Deaths

Jack Cush, MD

On August 2, the US Food and Drug Administration (FDA) will convene a hearing of the Arthritis Advisory Committee (AAC) to review the safety of the novel IL-6 inhibitor, sirukumab, being developed by Janssen (Johnson & Johnson).

Giant-Cell_Vasculitis.jpg

NEJM: Actemra Effective in Giant Cell Arteritis

Jack Cush, MD

On May 22, Genentech received FDA approval for the use of subcutaneous (sc) tocilizumab (TCZ) in patients with giant cell arteritis (GCA) – also known as temporal arteritis.

WIR.large_.jpg (keep)

The RheumNow Week in Review – 28 July 2017

Jack Cush, MD

Dr. Jack Cush reviews the news and articles from the past week on RheumNow.com:

OP_0.jpg

Denosumab Increases Trabecular Bone

Olga Petryna, MD

Bone mineral density (BMD) measurement vie DEXA scan commonly used to assess bone density and fracture risk in postmenopausal osteoporosis provides us with approximate assessment of bone health while lacking sensitivity in vertebral fracture risk prediction.

vial.infusion.jpg (keep)

Biosimilar Pricing Wars Have Begun

Jack Cush, MD

Despite the approval of four anti-TNF biosimilars in 12 months, their introduction into the U.S. market has been slow and - until now - with paultry discounts compared to their introduction throughout Europe, where discounts averaged 50% and were as high as 70% (compared to the price of Remicade).

Lupusfoto.jpg

Increased Pulmonary Embolism Risk in Lupus Patients

Jack Cush, MD

Systemic lupus erythematosus (SLE) poses numerous vascular risks, many of which are thought to be autoantibody mediated.

renal.genes_.jpg

Tubulointerstitial Damage in Lupus Predicts ESRD Progression

RheumNow

The presence of tubulointerstitial damage (TID) may provide a potential window for early intervention in lupus nephritis (LN) to ward off end-stage renal disease (ESRD), according to a data analysis.

detour.jpg

Baricitinib Derailed by FDA Review

Jack Cush, MD

Eli Lilly and Co disclosed today that upon further discussions with the US Food and Drug Administration (FDA) there would be a delay in further regulatory decisions regarding baricitinib, a JAK inhibitor, that is being developed for use in rheumatoid arthritis (RA).  

pen%20injector.jpg

Benlysta FDA Approved for Sub-Q Use in Lupus

Jack Cush, MD

The US Food and Drug Administration (FDA) has approved a new subcutaneous formulation of Benlysta (belimumab) for use in active, autoantibody‑positive Systemic Lupus Erythematosus (SLE) patients.

Biosimilar.survey.slides%202017.opener.jpg

Rheumatologists and Patients Concerns over Biosimilars - RheumNow “Live Vote” Results

Artie Kavanaugh, MD

The RheumNow “Live Vote” on the use, uptake and safety of biosimilars contrasts rheumatologist and patient views. Despite FDA approval and looming introduction, there is considerable concern, knowledge gaps and hesitancy regarding their uptake in the US. The survey's primary question demonstrates that less than one-third of US rheumatologists are prepared to adopt biosimilars when they are available.

HIV.virus_.jpg

Inflammatory and Autoimmune Diseases are Not Rare in HIV Patients

Jack Cush, MD

HIV infection and AIDs has been associated with numerous complications, presumably resulting from impaired immunity from infection.  Sporadic cases and small cohorts of patients with rheumatic and autoimmune syndromes have been described but epidemiology data on the prevalence is scarce.

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×